PMID- 36395495
OWN - NLM
STAT- MEDLINE
DCOM- 20221121
LR  - 20221121
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 15
IP  - 3
DP  - 2022 Nov 7
TI  - Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting 
      for Large B-cell Lymphoma: A Game Changer?
PG  - 73-80
LID - 10.56875/2589-0646.1025 [doi]
AB  - Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the 
      third-line (and beyond) setting in patients with large B-cell lymphoma (LBCL). 
      Until recently, high-dose chemotherapy followed by autologous hematopoietic cell 
      transplantation (auto-HCT) was considered the standard of care in the second-line 
      setting in patients demonstrating an objective response before the procedure. The 
      ZUMA-7 and TRANSFORM studies showed the benefit of axicabtagene ciloleucel and 
      lisocabtagene maraleucel, respectively, in patients refractory to or relapsing 
      within 12 months of first-line anthracycline-based chemoimmunotherapy. However, a 
      third trial (BELINDA study) using tisagenlecleucel failed to show a benefit in 
      the same setting compared to standard salvage chemoimmunotherapy followed by 
      auto-HCT. Several differences exist between these trials, including trial 
      designs, patient population, crossover permissibility, bridging therapy, and 
      end-point definitions. In this review, we summarize the current evidence for the 
      treatment of patients with LBCL in the third line and beyond and standard 
      treatment in the second line before CAR T therapy approval and interpret outcomes 
      of the three trials examining the role of CAR T therapy in the second line and 
      their impact in reshaping future practice.
FAU - Mohty, Razan
AU  - Mohty R
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation Program, 
      Mayo Clinic, Jacksonville, FL, USA.
FAU - Moustafa, Muhamad Alhaj
AU  - Moustafa MA
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation Program, 
      Mayo Clinic, Jacksonville, FL, USA.
FAU - Aljurf, Mahmoud
AU  - Aljurf M
AD  - Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi 
      Arabia.
FAU - Murthy, Hemant
AU  - Murthy H
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation Program, 
      Mayo Clinic, Jacksonville, FL, USA.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AD  - Division of Hematology-Oncology and Blood and Marrow Transplantation Program, 
      Mayo Clinic, Jacksonville, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221107
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects/methods
MH  - *Receptors, Chimeric Antigen/therapeutic use
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - Antigens, CD19/therapeutic use
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy/pathology
MH  - *Hematopoietic Stem Cell Transplantation
EDAT- 2022/11/18 06:00
MHDA- 2022/11/22 06:00
CRDT- 2022/11/17 17:12
PHST- 2022/06/07 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/11/17 17:12 [entrez]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2022/11/22 06:00 [medline]
AID - 2589-0646.1025 [pii]
AID - 10.56875/2589-0646.1025 [doi]
PST - epublish
SO  - Hematol Oncol Stem Cell Ther. 2022 Nov 7;15(3):73-80. doi: 
      10.56875/2589-0646.1025.